(Total Views: 86)
Posted On: 09/23/2025 4:09:37 PM
Post# of 140
NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Appoints Tomas J. Philipson, PhD as Strategic Advisor
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases, announced the appointment of Tomas J. Philipson, PhD as a Strategic Advisor. Dr. Philipson, an expert in U.S. economic and healthcare policy with extensive academic, business, and government experience, previously served as acting chairman of the White House Council of Economic Advisers and has advised FDA, CMS, and major healthcare initiatives. He currently serves as Managing Partner of MEDA Ventures and on several corporate boards. Soligenix CEO Christopher J. Schaber, PhD, said Philipson’s expertise and relationships will be instrumental as the company advances its lead product candidate HyBryte(TM) through confirmatory Phase 3 trials and toward commercialization. Dr. Philipson said he looks forward to supporting Soligenix’s mission to bring treatments for rare diseases with unmet medical needs to market.
NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://nnw.fm/SNGX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases, announced the appointment of Tomas J. Philipson, PhD as a Strategic Advisor. Dr. Philipson, an expert in U.S. economic and healthcare policy with extensive academic, business, and government experience, previously served as acting chairman of the White House Council of Economic Advisers and has advised FDA, CMS, and major healthcare initiatives. He currently serves as Managing Partner of MEDA Ventures and on several corporate boards. Soligenix CEO Christopher J. Schaber, PhD, said Philipson’s expertise and relationships will be instrumental as the company advances its lead product candidate HyBryte(TM) through confirmatory Phase 3 trials and toward commercialization. Dr. Philipson said he looks forward to supporting Soligenix’s mission to bring treatments for rare diseases with unmet medical needs to market.
NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://nnw.fm/SNGX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)
